Multiple Myeloma and Infections: Characterizing the Risks
Despite newer agents being available to patients with multiple myeloma, the rate of infections in this patient population has remained relatively unchanged.
Bone Cancer
BONE CANCER ADVISOR
FEATURED CONTENT
-
-
Time to Treatment Discontinuation Makes Headway as Real-World End Point
An analysis by members of the FDA showed that time to treatment discontinuation may be a viable end point to assess drug efficacy in the postmarketing setting. -
Cabozantinib a Viable Choice for Non-Clear Cell Renal Cell Carcinoma
There are no biomarkers ready that have been prospectively validated to help predict which patients with non-clear cell RCC might respond to cabozantinib. -
BMT Societies Issue Recommendations on Posttransplant Maintenance in HL/NHL
Use of maintenance therapy as a therapeutic strategy in posttransplant patients with HL and NHL is increasing in frequency -
The Downstream Effect of Misrepresented Clinical Trial Data
Data quality issues borne out in clinical trials don’t always reach peer reviewers, and as a result, may not reach prescribers, either.
BONE CANCER NEWS
FDA Grants Orphan Drug Designation to BN-Brachyury for Chordoma
CTA Treatment Regimen Chart for Bone Cancer Updated
Baseline EFS Outcomes Identified for Recurrent/Refractory Pediatric Osteosarcoma
In Giant Cell Tumor of Bone, Denosumab Shows Robust Clinical Efficacy
Pacritinib Reduces Spleen Volume in Patients with Myelofibrosis
Want to read more?
Please login or register first to view this content.
Next post in General Oncology
